Introduction {#H1-1-ZOI180024}
============

Patients with atrial fibrillation (AF) have a 5-fold increased risk of ischemic stroke and 20% to 30% of all strokes are generally attributed to AF.^[@zoi180024r1],[@zoi180024r2],[@zoi180024r3],[@zoi180024r4]^ Oral anticoagulation (OAC) therapy with either vitamin K antagonists or non--vitamin K antagonist oral anticoagulants reduces this risk by more than 60% and is recommended as both primary and secondary stroke prophylaxis in patients with AF with at least 1 to 2 risk factors for stroke according to the CHA~2~DS~2~-VASc (congestive heart failure; hypertension; ages ≥74 years \[2 points\]; diabetes; stroke, transient ischemic attack, or systemic embolism \[2 points\]; vascular disease; ages 65-74 years; sex \[female\]) risk score calculator.^[@zoi180024r2],[@zoi180024r3],[@zoi180024r5],[@zoi180024r6],[@zoi180024r7],[@zoi180024r8],[@zoi180024r9],[@zoi180024r10],[@zoi180024r11],[@zoi180024r12],[@zoi180024r13]^ However, significant underuse of OAC therapy in patients with AF has been reported in both Europe and the United States.^[@zoi180024r14],[@zoi180024r15],[@zoi180024r16],[@zoi180024r17],[@zoi180024r18],[@zoi180024r19],[@zoi180024r20],[@zoi180024r21],[@zoi180024r22]^

In patients with AF who have experienced a stroke, the 90-day risk of early recurrence and long-term recurrence have been reported to be 7.6% and approximately 18%, respectively.^[@zoi180024r23],[@zoi180024r24]^ However, studies regarding prestroke antithrombotic therapy in patients with AF presenting with stroke are limited and data regarding poststroke antithrombotic therapy in patients with AF and the relationship with the subsequent risk of stroke recurrence are sparse.^[@zoi180024r21],[@zoi180024r25]^ To address these gaps in knowledge, our aims were to examine prestroke and poststroke antithrombotic therapy in patients with AF admitted with ischemic stroke and to compare long-term outcomes in AF stroke survivors according to poststroke antithrombotic therapy.

Methods {#H1-2-ZOI180024}
=======

Data Sources {#H2-1-ZOI180024}
------------

The health care system in Denmark is tax financed and without any user charge (except for medication outside the hospital). Data from 4 high-quality nationwide registries were linked using a unique personal identifier number, which all residents are given at birth or immigration. The Danish Civil Registration System holds information about sex, emigration, and date of birth and death.^[@zoi180024r26]^ The Danish National Patient Registry holds information about all inpatient and outpatient hospital contacts, including diagnoses and length of hospital stay.^[@zoi180024r27]^ Diagnoses are registered in terms of *International Classification of Diseases* codes (*International Classification of Diseases, Eighth Revision* until 1994 and *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision* thereafter). The Danish Register of Causes of Death includes information about causes of death.^[@zoi180024r28]^ The Danish National Registry of Medicinal Statistics holds complete information about all filled prescriptions in Denmark but does not hold information about in-hospital prescriptions.^[@zoi180024r29]^ Approval from the research ethics committee system is not required in retrospective registry-based studies in Denmark and a waiver is granted so that informed consent does not have to be obtained. The Danish Data Protection Agency approved use of data for this study.

Study Patients {#H2-2-ZOI180024}
--------------

We identified all Danish residents with previously diagnosed AF (going back to 1978) who were admitted to a Danish hospital with ischemic stroke (including ischemic stroke, unspecified stroke, and transient ischemic attack \[TIA\]) from January 1, 2004, to January 31, 2017. According to European AF guidelines, we excluded those younger than 30 years, with valvular AF, and with a CHA~2~DS~2~-VASc score less than 1. The CHA~2~DS~2~-VASc score was calculated using a previously described method.^[@zoi180024r30]^ The remaining patients composed the prestroke population. We also defined a poststroke population that included those who survived a blanking period from hospital admission for stroke until 100 days after discharge. The study index date was set 100 days from stroke discharge to ensure complete information on poststroke antithrombotic treatment since packages of antithrombotic therapy in Denmark include tablets for a maximum of 100 days of treatment. Further, this blanking period ensured exclusion of those who died during their hospital admission for stroke or shortly after. The patients were divided in subgroups according to poststroke antithrombotic therapy and were followed up until June 30, 2017. In a sensitivity analysis, we restricted the patient inclusion to patients with AF admitted with stroke, and therefore excluded those admitted with TIA.

Antithrombotic Therapy {#H2-3-ZOI180024}
----------------------

We divided the prestroke and poststroke study population into 3 study groups according to prestroke and poststroke antithrombotic therapy: OAC therapy (including vitamin K antagonists and non--vitamin K antagonist oral anticoagulants with or without concomitant antiplatelet therapy), antiplatelet therapy alone (aspirin, adenosine diphosphate receptor inhibitors \[clopidogrel, prasugrel, and ticagrelor\], and dipyridamole), and no antithrombotic therapy. Prestroke antithrombotic therapy was defined as a filled prescription for antithrombotic therapy from 0 to 180 days before hospitalization for stroke. Poststroke antithrombotic therapy was defined as a filled prescription for antithrombotic therapy during the blanking period (0-100 days after stroke discharge). Due to differences in European and US guidelines, we performed a subgroup analysis of prestroke treatment patterns in patients with a prestroke CHA~2~DS~2~-VASc score of 2 or greater. See diagnosis codes and Anatomic Therapeutic Chemical Classification codes in eTable 1 in the [Supplement](#note-ZOI180024-1-s){ref-type="supplementary-material"}.

Outcomes {#H2-4-ZOI180024}
--------

The poststroke population was followed up from the index date until an outcome of interest, end of the study period (June 30, 2017), or emigration, whichever came first. The outcomes included thromboembolic events (ischemic stroke, unspecified stroke, TIA, and embolism or thrombosis in peripheral arteries), bleeding events, and death. Both AF and ischemic stroke were validated in the Danish registries with a positive predictive value of 93% and 97%, respectively, and two-thirds of unspecified strokes were classified as ischemic strokes by raters in a stroke validation study.^[@zoi180024r31],[@zoi180024r32]^

Statistical Analysis {#H2-5-ZOI180024}
--------------------

Patient demographic characteristics, comorbidities, CHA~2~DS~2~-VASc score, HAS-BLED (hypertension, abnormal renal or liver function, history of stroke, history of bleeding, international normalized ratio \[left out due to missing data\], ages ≥65 years, drug consumption with antiplatelet agents or nonsteroidal anti-inflammatory drugs, alcohol abuse) risk score for bleeding, and concomitant pharmacotherapy were assessed. The survival probability and cumulative incidence of thromboembolic events according to poststroke antithrombotic therapy were calculated using the Kaplan-Meier estimator and the Aalen-Johansen estimator (incorporating competing risk of death), respectively. The Gray test was used to test for difference in cumulative incidence of thromboembolic events. Crude and adjusted (age, sex, calendar year, comorbidities \[ischemic heart disease, peripheral artery disease, heart failure, coagulopathies, chronic kidney disease, chronic obstructive pulmonary disease, alcohol abuse, diabetes, thyroid disease, hypertension, prior bleeding events, pulmonary embolism, and deep venous thrombosis\], and concomitant pharmacotherapy \[ β-blockers, digoxin, amiodarone, verapamil, and flecainide\]) hazard ratios (HRs) were calculated by Cox regression models comparing long-term outcomes according to poststroke antithrombotic therapy. The Cox models were tested for proportional hazard assumptions and linearity of continuous variables. Clinically relevant interactions (sex, calendar year, comorbidities, CHA~2~DS~2~-VASc score, and HAS-BLED score) were assessed. Patient characteristics associated with prestroke and poststroke OAC therapy were assessed by multivariable logistic regression. A *P* value less than .05 was considered statistically significant. All statistical analyses were performed in SAS statistical software version 9.4 (SAS Institute Inc) or R software (R Foundation for Statistical Computing).

Results {#H1-3-ZOI180024}
=======

Prestroke Antithrombotic Therapy {#H2-6-ZOI180024}
--------------------------------

[Figure 1](#zoi180024f1){ref-type="fig"} depicts selection of the study population. From January 1, 2004, to January 31, 2017, 33 308 patients with AF presenting with ischemic stroke were admitted to Danish hospitals. After relevant exclusions, the prestroke study population comprised 30 626 patients. Of these, 11 139 patients (36.3%) received OAC therapy, 11 874 (38.8%) received antiplatelet therapy alone, and 7613 (24.9%) did not receive any antithrombotic therapy before their stroke. Time trends in prestroke antithrombotic treatment patterns are depicted in eFigure 1 in the [Supplement](#note-ZOI180024-1-s){ref-type="supplementary-material"}. The annual percentage of patients receiving OAC therapy before stroke ranged between 30.3% and 31.8% from 2004 to 2010. From 2010, this amount increased, reaching 58.5% in 2017.

![Patient Selection Flowchart\
CHA~2~DS~2~-VASc indicates risk score for stroke (congestive heart failure; hypertension; ages ≥74 years \[2 points\]; diabetes; stroke, transient ischemic attack, or systemic embolism \[2 points\]; vascular disease; ages 65-74 years; sex \[female\]).](jamanetwopen-1-e180171-g001){#zoi180024f1}

The baseline characteristics of the prestroke study population according to prestroke antithrombotic therapy are listed in the [Table](#zoi180024t1){ref-type="table"}. Patients receiving OAC therapy were slightly younger and less likely to be female (44.3% female; median age, 79 years \[interquartile range {IQR}, 73-85 years\]) than those who received antiplatelet therapy (55.0% female; median age, 82 years \[IQR, 75-88 years\]) or no antithrombotic therapy (53.8% female; median age, 80 years \[IQR, 71-86 years\]) before their hospital admission for stroke. No differences existed in CHA~2~DS~2~-VASc scores across the different treatment groups. Patients receiving no antithrombotic therapy had a lower estimated HAS-BLED score (median, 2 \[IQR, 1-3\]) than patients treated with either OAC (median, 3 \[IQR, 2-4\]) or antiplatelet therapy (median, 3 \[IQR, 3-4\]). When restricting the prestroke study population to patients with a CHA~2~DS~2~-VASc score of 2 or greater, 10 757 patients (36.5%) received OAC therapy, 11 574 (39.3%) received antiplatelet therapy, and 7106 (24.1%) received no antithrombotic therapy before their stroke diagnosis.

###### Baseline Characteristics at Stroke Hospital Admission According to Prestroke Antithrombotic Therapy in the Prestroke Population

  Characteristic                                               No. (%)                                     
  ------------------------------------------------------------ --------------- ------------- ------------- -------------
  Demographic                                                                                              
  Age, median (IQR), y                                         81 (73-86)      79 (73-85)    82 (75-88)    80 (71-86)
  Female                                                       15 563 (50.8)   4937 (44.3)   6527 (55.0)   4099 (53.8)
  Comorbidities                                                                                            
  Alcohol abuse                                                1419 (4.6)      411 (3.7)     568 (4.8)     440 (5.8)
  Cancer                                                       5597 (18.3)     2167 (19.5)   2045 (17.2)   1385 (18.2)
  Coagulopathies                                               636 (2.1)       339 (3.0)     166 (1.4)     131 (1.7)
  Chronic kidney disease                                       2349 (7.7)      912 (8.2)     961 (8.1)     476 (6.3)
  Chronic obstructive pulmonary disease                        4143 (13.5)     1578 (14.2)   1680 (14.2)   885 (11.6)
  Deep venous thrombosis                                       1245 (4.1)      596 (5.4)     397 (3.3)     252 (3.3)
  Dementia                                                     1677 (5.5)      417 (3.7)     921 (7.8)     339 (4.5)
  Diabetes                                                     4836 (15.8)     2089 (18.8)   1925 (16.2)   822 (10.8)
  Heart failure                                                7913 (25.8)     3290 (29.5)   3198 (26.9)   1425 (18.7)
  Hypertension                                                 19 363 (63.2)   8090 (72.6)   7850 (66.1)   3423 (45.0)
  Ischemic heart disease                                       11 099 (36.4)   4144 (37.2)   5274 (44.4)   1681 (22.1)
  Peripheral artery disease                                    2734 (8.9)      1073 (9.6)    1252 (10.5)   409 (5.4)
  Prior bleeding event                                         7963 (26.0)     3110 (27.9)   2935 (24.7)   1918 (25.2)
  Prior thromboembolic event                                   11 585 (37.8)   4267 (38.3)   4558 (38.4)   2760 (36.3)
  Pulmonary embolism                                           770 (2.5)       414 (3.7)     191 (1.6)     165 (2.2)
  Risk scores, median (IQR)                                                                                
  CHA~2~DS~2~-VASc[^c^](#zoi180024t1n3){ref-type="table-fn"}   4 (3-5)         4 (3-5)       4 (3-5)       4 (3-5)
  HAS-BLED[^d^](#zoi180024t1n4){ref-type="table-fn"}           3 (2-4)         3 (2-4)       3 (3-4)       2 (1-3)
  Pharmacotherapy                                                                                          
  Amiodarone                                                   795 (2.6)       425 (3.8)     291 (2.5)     79 (1.0)
  β-Blockers                                                   16 056 (52.4)   6920 (62.1)   6422 (54.1)   2714 (35.7)
  Digoxin                                                      9580 (31.3)     4426 (39.7)   3677 (31.0)   1477 (19.4)
  Flecainide                                                   292 (1.0)       131 (1.2)     101 (0.9)     60 (0.8)
  Verapamil                                                    2356 (7.7)      1078 (9.7)    880 (7.4)     398 (5.2)

Abbreviations: IQR, interquartile range; OAC, oral anticoagulation.

Includes vitamin K antagonists and non--vitamin K OAC with or without antiplatelet agent.

Includes aspirin, adenosine diphosphate receptor inhibitors (clopidogrel, prasugrel, and ticagrelor), and dipyridamole.

Risk score for stroke: congestive heart failure; hypertension; ages 74 years or older (2 points); diabetes; stroke, transient ischemic attack, or systemic embolism (2 points); vascular disease; ages 65 to 74 years; sex (female).

Risk score for bleeding: hypertension, abnormal renal or liver function, history of stroke, history of bleeding, international normalized ratio (left out due to missing data), ages 65 years or older, drug consumption with antiplatelet agents or nonsteroidal anti-inflammatory drugs, alcohol abuse.

Poststroke Antithrombotic Therapy {#H2-7-ZOI180024}
---------------------------------

Time trends in poststroke antithrombotic therapy are depicted in eFigure 2 in the [Supplement](#note-ZOI180024-1-s){ref-type="supplementary-material"}. Over the years, OAC treatment rates increased and reached 73.1% during the first 6 months of 2017. From the day of hospital admission for stroke until the index date of 100 days after stroke hospitalization, 19.9%, 26.5%, and 22.3% of patients treated with OAC therapy, antiplatelet therapy, and no antithrombotic therapy, respectively, before their stroke died. eTable 2 in the [Supplement](#note-ZOI180024-1-s){ref-type="supplementary-material"} illustrates patient characteristics at the index date for the poststroke population grouped by poststroke antithrombotic therapy. Patients treated with OAC therapy following stroke compared with those receiving antiplatelet therapy or no antithrombotic therapy were younger (median \[IQR\], 77 \[70-83\] years, 82 \[74-87\] years, and 80 \[74-87\] years, respectively), had a lower CHA~2~DS~2~-VASc risk score (median \[IQR\], 5 \[4-6\], 6 \[5-6\], and 5 \[4-6\], respectively), and had a lower HAS-BLED risk score (median \[IQR\], 4 \[3-4\], 4 \[4-5\], and 3 \[3-4\], respectively).

Prestroke to Poststroke Change in Antithrombotic Therapy {#H2-8-ZOI180024}
--------------------------------------------------------

Treatment shifts from before stroke to after stroke among the poststroke population are depicted in [Figure 2](#zoi180024f2){ref-type="fig"}. The proportion of patients receiving OAC therapy increased from before stroke to after stroke (36.3% vs 52.5%). Of those treated with OAC therapy, antiplatelet therapy, or no antithrombotic therapy before their hospital admission for stroke, 79.0%, 58.7%, and 16.9%, respectively, continued to receive the same treatment after discharge. Following stroke, 31.3% of those receiving antiplatelet therapy alone and 43.7% of those receiving no antithrombotic therapy before stroke shifted to OAC therapy. Yet, 37.5% of patients with stroke did not receive OAC therapy following stroke.

![Prestroke to Poststroke Shifts in Antithrombotic Therapy Among Poststroke Study Population](jamanetwopen-1-e180171-g002){#zoi180024f2}

Long-term Outcomes According to Poststroke Antithrombotic Therapy {#H2-9-ZOI180024}
-----------------------------------------------------------------

The median follow-up time from the index date to study outcome, death, emigration, or study end was 2.2 years (IQR, 0.8-4.6 years). [Figure 3](#zoi180024f3){ref-type="fig"} shows the cumulative incidence of thromboembolic events and deaths according to poststroke antithrombotic therapy. During a maximum of 10 years of follow-up, 17.5%, 21.2%, and 21.5% experienced a new thromboembolic event and 72.7%, 86.4%, and 86.2% died among those treated with OAC therapy, antiplatelet therapy, or no antithrombotic therapy, respectively.

![Thromboembolic Events and Death by Poststroke Treatment Group\
A, Cumulative incidence of thromboembolic events. B, Kaplan-Meier curve for death.](jamanetwopen-1-e180171-g003){#zoi180024f3}

The long-term risks of stroke (adjusted HR, 0.81; 95% CI, 0.73-0.89) and death (adjusted HR, 0.68; 95% CI, 0.65-0.72) were significantly lower among patients treated with OAC therapy compared with no antithrombotic therapy ([Figure 4](#zoi180024f4){ref-type="fig"}). In contrast, no significant differences existed for those treated with antiplatelet therapy compared with no antithrombotic therapy (thromboembolic event: adjusted HR, 1.01; 95% CI, 0.92-1.12; death: adjusted HR, 0.95; 95% CI, 0.91-1.00). When comparing the long-term risk of bleeding events according to poststroke antithrombotic therapy, no statistically significant differences were found for OAC therapy (adjusted HR, 0.97; 95% CI, 0.86-1.10) compared with no antithrombotic therapy. The restriction of the study population to patients with a prestroke CHA~2~DS~2~-VASc score of 2 or greater did not change the results (eFigure 3 in the [Supplement](#note-ZOI180024-1-s){ref-type="supplementary-material"}).

![Incidence Rates and Adjusted Hazard Ratios of Long-term Outcomes (Thromboembolic Event and Death) According to Poststroke Treatment\
Covariates in the adjusted model included age at study start, sex, calendar year, comorbidities (ischemic heart disease, peripheral artery disease, heart failure, prior pulmonary embolism, prior deep venous thrombosis, coagulopathies, chronic kidney disease, prior bleeding event, alcohol abuse, diabetes, hypertension, and chronic obstructive pulmonary disease), and concomitant pharmacotherapy (including β-blockers, digoxin, amiodarone, verapamil, and flecainide).](jamanetwopen-1-e180171-g004){#zoi180024f4}

When excluding patients admitted with TIA, the prestroke population consisted of 26 708 patients. With regard to long-term outcomes, the results were similar to those from the main analysis (eFigure 4 in the [Supplement](#note-ZOI180024-1-s){ref-type="supplementary-material"}).

Factors Associated With OAC Therapy {#H2-10-ZOI180024}
-----------------------------------

Factors associated with prestroke and poststroke OAC therapy are depicted in eFigure 5 and eFigure 6 in the [Supplement](#note-ZOI180024-1-s){ref-type="supplementary-material"}. For the analysis of the prestroke population, being male, being older than 74 years, and several comorbidities (coagulopathies, deep venous thrombosis, diabetes, heart failure, hypertension, ischemic heart disease, peripheral artery disease, and pulmonary embolism) were associated with OAC therapy, and alcohol abuse, chronic kidney disease, dementia, and prior bleeding events were associated with no OAC therapy. The CHA~2~DS~2~-VASc score was not associated with the prestroke treatment category. For the poststroke analysis, ages 65 to 74 years (compared with ages \<65 years), being male, deep venous thrombosis, and hypertension were associated with OAC therapy. Ages greater than 74 years, alcohol abuse, cancer, chronic kidney disease, chronic obstructive pulmonary disease, dementia, ischemic heart disease, and prior bleeding events were associated with no OAC therapy.

Discussion {#H1-4-ZOI180024}
==========

We examined prestroke and poststroke antithrombotic therapy in patients with AF with a CHA~2~DS~2~-VASc score of 1 or greater presenting with ischemic stroke, and further related treatment patterns with subsequent long-term outcomes. The study yielded 4 main findings. First, before stroke, almost two-thirds of patients with AF did not receive OAC therapy as recommended by guidelines. Second, after stroke about half of the stroke survivors did not receive OAC therapy. However, prestroke and poststroke treatment rates increased over time. Third, approximately 1 of 5 of those who survived a stroke had a new stroke during follow-up (median, 2.2 years). Fourth, poststroke OAC therapy was associated with a significantly lower risk of a new thromboembolic event without increased risk of bleeding complications compared with antiplatelet therapy or no poststroke antithrombotic therapy. Taken together, these findings suggest substantial opportunities for improvement of both primary and secondary stroke prevention in intermediate- to high-risk patients with AF.

Prestroke Antithrombotic Therapy {#H2-11-ZOI180024}
--------------------------------

The prestroke use of OAC increased over time, reaching 58.5% in 2017. During the 1990s, several studies showed benefits from OAC therapy (with vitamin K antagonists) instead of aspirin for thromboprophylaxis in patients with AF.^[@zoi180024r33],[@zoi180024r34],[@zoi180024r35],[@zoi180024r36]^ European guidelines changed in 2010, recommending OAC therapy and not aspirin for stroke prevention in patients with AF.^[@zoi180024r37]^ Since then, an increase of OAC therapy has been observed in Denmark among patients with AF,^[@zoi180024r17]^ which is in accordance with this study. Nevertheless, the percentage of eligible patients not receiving any antithrombotic therapy remained approximately 23% even after the new guideline recommendations. Because patients had to pick up the medication at a pharmacy to be registered in a treatment group, bad compliance may have accounted for some part of the patients in the group receiving no antithrombotic therapy. Recently, Xian et al^[@zoi180024r13]^ investigated prestroke antithrombotic therapy in patients with AF presenting with acute ischemic stroke and the association with stroke severity in the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research study including national stroke data from the United States.^[@zoi180024r21],[@zoi180024r38]^ In that cohort, approximately 30% received OAC therapy before their stroke diagnosis, 40% received antiplatelet therapy alone, and 30% did not receive any prestroke antithrombotic therapy. These findings are consistent with ours, although Xian and colleagues^[@zoi180024r13]^ were unable to study subsequent treatment patterns and outcomes.

Poststroke Antithrombotic Therapy {#H2-12-ZOI180024}
---------------------------------

After stroke, 1 in 3 of those who received antiplatelet therapy before stroke shifted to OAC therapy, while almost half of those with no prestroke antithrombotic therapy shifted to OAC therapy. Despite this, almost half of the poststroke population still did not receive OAC therapy. However, treatment rates increased over time. Unfortunately, we had no data on contraindications for OAC therapy and physicians' considerations when choosing not to prescribe OAC therapy at discharge. In the recent study by Xian et al^[@zoi180024r13]^ using data from the Get With the Guidelines--Stroke program with access to patient files, the most common reasons not to prescribe OAC therapy in patients with AF after stroke were risk of bleeding (16.3%), risk of falls (10.3%), and terminal illness (6.2%). However, 65.8% of the patients did not have a documented reason for no OAC therapy.^[@zoi180024r21]^

In previous studies, we found an association between older age, higher HAS-BLED score, and more comorbidities and no poststroke OAC therapy.^[@zoi180024r39],[@zoi180024r40]^ This could reflect a caution among physicians in the prescription of OAC therapy for older patients, even though they are at high risk of stroke. However, Appelros and colleagues^[@zoi180024r39]^ recently showed a beneficial effect of OAC therapy for stroke prophylaxis in patients older than 80 years.

Recurrent Thromboembolic Events {#H2-13-ZOI180024}
-------------------------------

Several studies have examined early recurrence in patients with AF presenting with stroke,^[@zoi180024r23],[@zoi180024r41],[@zoi180024r42]^ and a few have looked into the long-term risks.^[@zoi180024r24],[@zoi180024r39],[@zoi180024r43]^ Wu et al^[@zoi180024r24]^ found a stroke recurrence rate among patients with AF of 18% during a median follow-up of 2.4 years from stroke hospitalization. This is in accordance with our finding. Patients receiving OAC therapy had a significantly lower risk of a recurrent thromboembolic event compared with those receiving no antithrombotic therapy. Further, no decrease in thromboembolic risk was found for those receiving poststroke antiplatelet therapy. This in part may be related to the possible effectiveness of OAC therapy as secondary stroke prevention in patients with AF. Our results also showed an association between poststroke OAC therapy and lower risk of death. Regarding bleeding events, no significant differences were found across treatment groups. This may be because of residual confounding and confounding by indication, which should be kept in mind when interpreting our results.

Limitations {#H2-14-ZOI180024}
-----------

This was a retrospective observational study, and no causations can be drawn. Our registries did not include factors such as alcohol consumption or fall tendency. Also, all types of AF were included in the study, and hence also AF occurring secondary to other conditions (eg, postoperative AF). These are factors that may influence the physicians' choice of antithrombotic therapy. Also, no information on labile international normalized ratio was available for this population, possibly leading to an overestimation of patients receiving adequate OAC therapy. The Danish National Registry of Medicinal Statistics registers redeemed prescriptions, and patients had to pick the medication up to be included in either the OAC or antiplatelet therapy group. Therefore, our results may have been influenced by patient compliance. Moreover, the definition of ischemic stroke included TIA and strokes without classification as hemorrhagic or thrombotic. This may have led to some degree of misclassification. To ensure complete data on antithrombotic therapy, we constructed a blanking period from hospital discharge to 100 days following stroke. During this blanking period several patients died and some of the patients likely had a recurrent thromboembolic event or experienced a bleeding event. This may have led to underestimation of events in the poststroke population. Importantly, this study was based on very high-quality data with nationwide patient inclusion and complete and long-term follow-up ensuring an unbiased selection of study group without loss of follow-up.

Conclusions {#H1-5-ZOI180024}
===========

Among patients with AF having an ischemic stroke, OAC therapy rates seemed low both before and after stroke. However, an increase in treatment rates was observed over time. Oral anticoagulation therapy was associated with a significantly lower risk of thromboembolic events without excess risk of bleeding complications compared with antiplatelet therapy and no antithrombotic therapy. This study suggests a substantial opportunity for improving primary and secondary stroke prophylaxis in patients with AF.
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